WebDoctor Encyclopedia

Melanoma

Uveal melanoma

Uveal melanoma is the most common eye cancer in adults. It starts in the pigment cells of the iris, ciliary body or choroid and can spread to the liver.

Medically reviewed Last reviewed October 27, 2026

What is uveal melanoma?

Uveal melanoma is a cancer that starts in the pigment cells (melanocytes) of the uvea, the middle layer of the eye. The uvea has three parts: the coloured iris at the front, the ciliary body behind it and the choroid, a layer rich in blood vessels that lies under the retina at the back of the eye.

It is the most common cancer that starts inside the eye in adults. Even so, it is rare, and it is a very different disease from melanoma of the skin. It has its own genetic changes, it is not clearly linked with sunburn, and it spreads mainly through the bloodstream, most often to the liver.

Most uveal melanomas can be treated successfully inside the eye, often without removing it. The main challenge is the risk of spread, which can appear years later. For this reason, genetic testing of the tumour and long-term follow-up are an important part of care.

1. How common is it?

Uveal melanoma is diagnosed in about 5 people per million each year in the United States and in Europe. Rates are higher in northern Europe than in the south, and the disease is rare in people of African or Asian descent.

Feature Details
Share of all melanomas About 3-5%
Typical age Most often 50-70; median about 60
Sex Slightly more common in men
Location in the eye Choroid about 90%, ciliary body about 6%, iris about 4%
Usually affects One eye only

2. Causes and risk factors

The exact cause is not known. The tumour develops when melanocytes in the uvea gain genetic changes that make them grow out of control.

Risk factor What it means
Fair skin and light eyes Blue, green or grey eyes and skin that burns easily carry a higher risk
Choroidal naevus A common “freckle” at the back of the eye; only a very small number turn into melanoma
Ocular melanocytosis Extra pigment in the eye and surrounding skin (naevus of Ota); raises the lifetime risk to about 1 in 400
BAP1 tumour predisposition syndrome A rare inherited condition that also raises the risk of mesothelioma, kidney cancer and skin melanoma
Older age Risk rises with age

Unlike skin melanoma, sunlight has not been proven to be a major cause of melanoma of the choroid or ciliary body. The lens and cornea filter much of the ultraviolet light before it reaches the back of the eye. Iris melanomas, which sit at the front, may be more related to sun exposure.

Genetic changes in the tumour

Almost all uveal melanomas carry a mutation in one of two related genes, GNAQ or GNA11. These are early changes and do not on their own predict outcome.

Later changes are much more important for prognosis:

Change How often What it means
Loss of one copy of chromosome 3 (monosomy 3) About half of tumours Strongly linked with a higher risk of spread
BAP1 mutation or loss Most tumours that spread High risk; usually goes together with monosomy 3
Gain of chromosome 8q Common Adds to the risk, especially with monosomy 3
SF3B1 mutation About 1 in 5 Intermediate risk; spread may occur late
EIF1AX mutation About 1 in 7 Low risk
Gain of chromosome 6p Common in low-risk tumours Usually favourable

3. How does it look?

Uveal melanoma is usually hidden inside the eye. Only iris melanomas can sometimes be seen in a mirror. The others are seen by an eye doctor looking through a dilated pupil, and on special scans.

3.1 What the eye doctor sees

Choroidal melanoma usually looks like a raised, dome-shaped lump under the retina. It is most often brown or grey, but some tumours have little pigment and look yellowish or pale (amelanotic melanoma).

As the tumour grows, it may break through a thin membrane under the retina (Bruch’s membrane). It then takes on a typical mushroom or “collar-button” shape.

Signs that suggest a melanoma rather than a harmless naevus include:

  • Thickness of more than 2 mm
  • Fluid under the retina, which can cause a partial retinal detachment
  • Orange pigment (lipofuscin) on the surface
  • A position close to the optic disc
  • No drusen (small yellow deposits) and no pale halo, which are typical of long-standing benign naevi

Eye doctors often remember these with the phrase “To Find Small Ocular Melanoma Using Helpful Hints Daily”. Each letter stands for one warning sign: thickness, fluid, symptoms, orange pigment, margin near the disc, ultrasound hollowness, halo absent and drusen absent.

Ciliary body melanoma is hidden behind the iris and is often found late. Sometimes a few large, twisted blood vessels (sentinel vessels) appear on the white of the eye over the tumour. The tumour may push against the lens and cause a cataract or blurred vision.

Iris melanoma appears as a brown, or sometimes pale, spot or lump on the coloured part of the eye. It may change the shape of the pupil, pull pigment onto the front of the iris or bleed into the front of the eye.

3.2 On scans

Test Typical appearance
Fundus photography Records size, colour and orange pigment for comparison over time
Ultrasound (B-scan and A-scan) Solid lump with low-to-medium internal reflectivity, “acoustic hollowness” and sometimes a dip in the underlying choroid
Optical coherence tomography (OCT) Fluid under the retina and changes in the retinal layers over the tumour
Autofluorescence imaging Bright spots where orange pigment is present
Ultrasound biomicroscopy Detailed images of iris and ciliary body tumours
MRI Bright on T1 and dark on T2 images because of melanin; shows any growth outside the eye

3.3 Under the microscope

Pathologists describe the tumour cells as spindle cells (long and thin) or epithelioid cells (larger and rounder). Many tumours are mixed. Tumours with more epithelioid cells have a higher risk of spread.

Special stains such as Melan-A, HMB-45, S100 and SOX10 confirm that the tumour is a melanoma. Loss of BAP1 staining in the cell nuclei suggests a high-risk tumour.

4. Symptoms

Many people have no symptoms. In about a third of cases the tumour is found during a routine eye test or an examination for new glasses.

When symptoms occur, they depend on where the tumour is and how large it is. They are usually painless.

Symptom Why it happens
Blurred or reduced vision Tumour or fluid under the central retina
Flashes of light Fluid lifting or irritating the retina
Floaters Small specks, shadows or blood in the jelly of the eye
A shadow or “curtain” A partial retinal detachment
Loss of part of the field of vision Tumour or detachment in the side of the retina
Distorted vision Straight lines look wavy when the centre of the retina is affected
A dark spot on the iris Growing or changing iris melanoma
Change in pupil shape Iris or ciliary body tumour pulling on the iris

Less common symptoms include a red, painful eye from raised eye pressure (glaucoma) and changes in focusing or glare from a ciliary body tumour pressing on the lens.

If the cancer has spread to the liver, people may notice tiredness, loss of appetite, weight loss or discomfort under the right ribs. More often, though, liver spread is first found on routine scans.

When to see a doctor

See an optician or eye doctor promptly if you notice new flashes, floaters, a shadow in your vision, blurred or distorted vision, or a new or growing dark spot on the iris. These symptoms have many harmless causes, but they always need an eye examination.

5. Diagnosis

Uveal melanoma is usually diagnosed by an ocular oncologist, an eye specialist who treats eye tumours. In most cases the diagnosis is made from the appearance of the tumour and imaging tests, without a biopsy.

5.1 Eye examination and imaging

The specialist examines the eye through a dilated pupil and measures the tumour with ultrasound. Photographs and OCT scans are taken for comparison at later visits. A small, suspicious lesion may be watched for growth before treatment is decided.

5.2 Biopsy and genetic testing

A fine-needle biopsy is done when the diagnosis is uncertain, or to obtain tissue for prognostic genetic tests. It is often taken at the time of radiotherapy or surgery.

The tumour sample can be tested in two main ways:

  • Chromosome testing, which looks for monosomy 3, gain of 8q and other changes
  • Gene expression profiling (for example the DecisionDx-UM test, used mainly in the United States), which sorts tumours into Class 1A, Class 1B and Class 2. In a prospective study, the five-year risk of spread was about 2%, 21% and 72% for these three classes.

These results do not change how the eye tumour is treated. They help decide how often to scan the liver and whether to offer a clinical trial.

5.3 Checking for spread

Before treatment, most centres check the liver with MRI or ultrasound, and sometimes do a CT scan of the chest and abdomen. Blood tests of liver function are not reliable enough on their own. At diagnosis, fewer than 4% of people have visible spread.

5.4 Conditions that can look similar

  • Choroidal naevus, a flat or slightly raised benign freckle
  • Metastasis from another cancer, such as breast or lung cancer, which is often pale and may affect both eyes
  • Choroidal haemangioma, a benign orange-red tumour of blood vessels
  • Bleeding under the retina, for example from age-related macular degeneration

6. Staging

Uveal melanoma is staged with the AJCC TNM system (8th edition). The tumour is first placed in one of four size categories based on its largest base diameter and thickness. It is then given extra letters if it involves the ciliary body or has grown outside the eye.

Stage What it means in general
I Small tumour, limited to the choroid
II (A, B) Small to medium tumour, or small tumour involving the ciliary body
III (A, B, C) Larger tumour, often with ciliary body involvement or growth outside the eye
IV Spread to lymph nodes or distant organs, most often the liver

Many doctors also still use the size groups from the large Collaborative Ocular Melanoma Study (COMS): small, medium and large tumours.

7. Treatment

Treatment aims to destroy the tumour, keep the eye and as much sight as possible, and reduce the risk of complications. The choice depends on the size and position of the tumour, the vision in both eyes, and the person’s age, health and wishes.

The COMS trial showed that, for medium-sized tumours, radiotherapy with a plaque gives the same survival as removing the eye. Most people today keep their eye.

7.1 Treatments for the eye tumour

Treatment How it works Best suited for Main drawbacks
Plaque brachytherapy A small disc with iodine-125 or ruthenium-106 seeds is stitched to the eye wall over the tumour for a few days Most small and medium tumours Radiation damage to the retina or optic nerve, cataract
Proton beam therapy Precisely targeted external radiotherapy, usually in four or five sessions Tumours near the optic nerve or centre of vision, and larger tumours Available in few centres; dry eye, lash loss, retinal damage
Stereotactic radiotherapy Focused photon beams (for example Gamma Knife or CyberKnife) Selected tumours where protons are not available Similar to proton therapy
Local resection The tumour is cut out through the eye wall or from inside the eye Selected iris, ciliary body and thick choroidal tumours Specialised surgery; risk of bleeding and retinal detachment
Enucleation Removal of the eye, followed by an implant and an artificial eye Very large tumours, growth outside the eye, painful blind eye Loss of the eye
Laser (transpupillary thermotherapy) Heat from an infrared laser Now rarely used alone; sometimes added to radiotherapy Higher risk of regrowth when used alone

After radiotherapy, the tumour usually shrinks slowly over months to years but often does not disappear completely. The tumour stays under control in more than 90% of cases.

7.2 Side effects of eye treatment

Radiation damage to the blood vessels of the retina (radiation retinopathy) is the main cause of vision loss after treatment. It usually develops after one to three years.

It can often be slowed with injections into the eye of anti-VEGF drugs or steroids, the same medicines used for macular degeneration. Cataract can be treated with routine surgery. Some people lose useful sight in the treated eye, especially when the tumour lies close to the centre of vision or the optic nerve.

After enucleation, an artificial eye is fitted, which looks natural and moves with the other eye. Most people adapt well to seeing with one eye, although judging distances can take some practice.

7.3 Treatment of spread (metastatic uveal melanoma)

About half of people with uveal melanoma eventually develop metastases, even after successful treatment of the eye. The liver is affected in about 90% of these cases. Treatment of metastatic uveal melanoma differs from that of skin melanoma.

Treatment Who may benefit Key facts
Tebentafusp Adults whose tissue type is HLA-A*02:01 (about half of white Europeans) Weekly infusion; first drug shown to improve survival (median 21.7 vs 16.0 months in the phase 3 trial)
Liver surgery or ablation A few metastases limited to the liver Can give long periods of control in carefully selected people
Liver-directed therapy Disease mainly in the liver Includes melphalan delivered directly to the liver (percutaneous hepatic perfusion), chemoembolisation and radioembolisation
Ipilimumab plus nivolumab People who cannot receive tebentafusp Response in about 1 in 10 to 1 in 5 people, much lower than in skin melanoma
Clinical trials Everyone with metastatic disease New targeted drugs and cell therapies are being tested

There is currently no proven adjuvant treatment that prevents metastases after treatment of the eye tumour. People with high-risk tumours may be offered a clinical trial.

8. Prognosis

The outlook for the eye itself is usually good. The overall outlook depends mainly on whether the cancer spreads.

According to the American Cancer Society, using US data for people diagnosed between 2015 and 2021, five-year relative survival for eye melanoma is:

Stage at diagnosis 5-year relative survival
Localised (inside the eye) About 88%
Regional (nearby tissues or lymph nodes) About 65%
Distant (for example the liver) About 19%
All stages combined About 84%

Factors linked with a higher risk of spread include:

  • A large or thick tumour
  • Involvement of the ciliary body
  • Growth outside the eye
  • Epithelioid cells under the microscope
  • Monosomy 3, BAP1 loss or a Class 2 gene expression profile

Metastases can appear many years after treatment, sometimes after more than ten years. Historically, median survival after metastases were found was about one year. Newer treatments and liver-directed therapies are now extending survival for some people.

9. Follow-up and living with uveal melanoma

9.1 Eye follow-up

After treatment, the eye is checked regularly, often every 3-6 months at first and then less often. Visits include photographs and ultrasound to confirm that the tumour is shrinking or stable, and checks for radiation side effects.

9.2 Liver surveillance

Liver scans are usually advised for at least ten years. Many centres use MRI or ultrasound every 6-12 months, or every 3-6 months for people with high-risk tumours. Finding metastases early may allow surgery or liver-directed treatment while the disease is limited.

9.3 Everyday life

  • Most people can return to work and normal activities soon after treatment.
  • Ask about driving: the rules depend on the vision in both eyes and differ between countries.
  • Wearing sunglasses outdoors protects the eyes and is sensible after radiotherapy.
  • Low-vision services can help if the sight in the treated eye is reduced.
  • Worry about recurrence is common. Patient organisations for ocular melanoma and specialist nurses offer support and reliable information.
  • Relatives usually do not need screening. Genetic counselling may be offered if there is a family history of uveal melanoma, mesothelioma or kidney cancer, which may suggest a BAP1 syndrome.

Resources

  1. Jager, M.J. et al. (2020) ‘Uveal melanoma’, Nature Reviews Disease Primers, 6(1), p. 24.
  2. Kaliki, S. and Shields, C.L. (2017) ‘Uveal melanoma: relatively rare but deadly cancer’, Eye, 31(2), pp. 241-257.
  3. Collaborative Ocular Melanoma Study Group (2006) ‘The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28’, Archives of Ophthalmology, 124(12), pp. 1684-1693.
  4. Onken, M.D. et al. (2012) ‘Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma’, Ophthalmology, 119(8), pp. 1596-1603.
  5. Harbour, J.W. et al. (2010) ‘Frequent mutation of BAP1 in metastasizing uveal melanomas’, Science, 330(6009), pp. 1410-1413.
  6. Shields, C.L. et al. (2009) ‘Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases’, Archives of Ophthalmology, 127(8), pp. 981-987.
  7. Nathan, P. et al. (2021) ‘Overall survival benefit with tebentafusp in metastatic uveal melanoma’, New England Journal of Medicine, 385(13), pp. 1196-1206.
  8. Rantala, E.S., Hernberg, M. and Kivela, T.T. (2019) ‘Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis’, Melanoma Research, 29(6), pp. 561-568.
  9. National Cancer Institute (2026) Intraocular (Uveal) Melanoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq (Accessed: October 2026).
  10. American Cancer Society (2026) Survival Rates for Eye Cancer (Melanoma of the Eye). Available at: https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html (Accessed: October 2026).

Prepared by the editorial team, October 2026.